logowsbdaily | Tue, 20 Dec 2022 03:11:26 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

MannKind Corporation
(MNKD)

MannKind Corporation
30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
United States
818 661 5000
www.mannkindcorp.com
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeu... Read More

Summary & Charts

Price$ 5.11+0.33 (+6.9%)
Day's Range$ 4.66 - 5.30 
Previous Close$ 4.78
Market Cap$ 1.27B USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqGM
IndustryBiotechnology
SectorHealthcare
Volume18.24M
Avg. Volume (20 day)4.55M
Rel. Volume (20 day)4.01
Rel. Volume (3 month)4.06
RatingB-Neutral
DCFN/AStrong Buy
Debt/Equity-223.63 %Sell
ROE42.12 %Neutral
ROA-33.32 %Neutral
P/E-13.63 %Strong Sell
P/B-5.57 %Strong Sell
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Dec 16, 2022$ 4.70$ 5.30$ 4.66$ 5.11+0.3318,237,2414.014.062
Dec 15, 2022$ 4.91$ 4.95$ 4.74$ 4.78-0.174,572,3701.201.01
Dec 14, 2022$ 4.87$ 5.05$ 4.80$ 4.95+0.064,854,0181.271.07
Dec 13, 2022$ 4.90$ 4.93$ 4.67$ 4.89+0.055,557,6661.461.23
Dec 12, 2022$ 4.64$ 4.87$ 4.51$ 4.84+0.176,014,0371.571.33
Dec 09, 2022$ 4.80$ 4.87$ 4.66$ 4.67-0.154,452,6391.150.99
Dec 08, 2022$ 4.70$ 4.84$ 4.65$ 4.82+0.122,955,2520.730.651
Dec 07, 2022$ 4.53$ 4.71$ 4.49$ 4.70+0.133,191,0170.750.70
Dec 06, 2022$ 4.62$ 4.62$ 4.52$ 4.57-0.043,202,3510.740.71
Dec 05, 2022$ 4.81$ 4.81$ 4.57$ 4.61-0.213,850,5440.880.85
Dec 02, 2022$ 4.60$ 4.84$ 4.54$ 4.82+0.164,114,2380.910.91
Dec 01, 2022$ 4.66$ 4.72$ 4.53$ 4.66-0.023,812,0420.850.84
Nov 30, 2022$ 4.46$ 4.70$ 4.40$ 4.68+0.255,390,1161.191.20
Nov 29, 2022$ 4.43$ 4.55$ 4.42$ 4.43+0.023,004,2350.680.67
Nov 28, 2022$ 4.45$ 4.55$ 4.39$ 4.41-0.103,325,9240.740.74
Nov 25, 2022$ 4.41$ 4.55$ 4.34$ 4.51+0.081,795,4430.400.40
Nov 23, 2022$ 4.39$ 4.50$ 4.38$ 4.433,438,0280.750.75
Nov 22, 2022$ 4.38$ 4.43$ 4.22$ 4.43+0.134,164,9290.890.91
Nov 21, 2022$ 4.18$ 4.33$ 4.17$ 4.30+0.102,434,7040.530.53
Nov 18, 2022$ 4.30$ 4.31$ 4.16$ 4.20-0.022,539,7410.550.55

News

The latest news about MannKind Corporation (MNKD).

Seeking Alpha | 2022-11-22 22:57:32
MannKind Is Poised To Turn A Profit And Shares Could Get Cheaper
MannKind Corp's bright future sets it apart from many in the disappointing biotech industry. Strong growth in the global next-generation diabetic products market will help MannKind Corp to generate net profit.
GlobeNewsWire | 2022-11-10 06:05:00
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
WESTLAKE VILLAGE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will present data from two posters on November 10 during the 22nd Annual Diabetes Technology Meeting's virtual poster session.
Seeking Alpha | 2022-11-08 15:14:02
MannKind Corporation (MNKD) Q3 2022 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q3 2022 Results Conference Call November 8, 2022 9:00 AM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Gregory Renza - RBC Capital Markets Robert Hazlett - BTIG Operator Good morning. And welcome to the MannKind Corporation Third Quarter 2022 Earnings Call.
GlobeNewsWire | 2022-11-01 06:00:00
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM (Eastern Time) on Tuesday, November 8, 2022.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-11-08AMC-0.09-0.0633.34%------
2022-08-09AMC-0.09-0.1122.22%------
2022-05-05AMC-0.1-0.10--12M12M--
2022-02-24AMC-0.07-0.1157.14%17M13M-26.69%
2021-11-09AMC-0.05-0.0420%21M22M7.71%
2021-08-11AMC-0.04-0.0525%17M23M33.1%
2021-05-12AMC-0.04-0.0525%13M17M33.33%
2021-02-25BMO-0.04-0.0650%15M18M21.21%

Top Discussions

These are the top discussions over the last 24-hours that mention the MNKD stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.